At the request of the members of the Beneluxa initiative (Belgium, the Netherlands, Luxembourg, Austria and Ireland) the market entry in Europe for medicines which lack conclusive evidence in…
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Joint statement at EPSCO Council June 2022: Market entry in Europe for drugs - evidence gaps and potential solutions
Pharmaceutical Developments on Haemophilia
This report, written by the Taskforce Horizon Scanning of the Beneluxa Initiative, describes the current situation of Haemophilia and provides an overview of new pharmaceutical developments regarding…
Joint HTA assessment on autologous gene therapy Libmeldy ongoing
The company Orchard Therapeutics (Netherlands) BV has stated its willingness to participate in a joint assessment of the autologous gene therapy Libmeldy (atidarsagene autotemcel) within the…